Photodynamic therapy (PDT) is believed to promote hypoxic conditions to tumor cells leading to overexpression of angiogenic markers such as vascular endothelial growth factor (VEGF). In this study, PDT was combined with lipid–calcium–phosphate nanoparticles (LCP NPs) to deliver VEGF-A small interfering RNA (siVEGF-A) to human head and neck squamous cell carcinoma (HNSCC) xenograft models. VEGF-A were significantly decreased for groups treated with siVEGF-A in human oral squamous cancer cell (HOSCC), SCC4 and SAS models. Cleaved caspase-3 and in situ TdT-mediated dUTP nick-end labeling assay showed more apoptotic cells and reduced Ki-67 expression for treated groups compared to phosphate buffered saline (PBS) group. Indeed, the combined therapy showed significant tumor volume decrease to ~70 and ~120% in SCC4 and SAS models as compared with untreated PBS group, respectively. In vivo toxicity study suggests no toxicity of such LCP NP delivered siVEGF-A. In summary, results suggest that PDT combined with targeted VEGF-A gene therapy could be a potential therapeutic modality to achieve enhanced therapeutic outcome for HNSCC.
Herein, a cysteine-functionalized alginate was used to replace cytotoxic cetyltrimethylammonium bromide (CTAB) on gold nanorods (GNRs) by gold–thiol bonding. The characterization shows that the alginate-modified GNRs (GNR@Alg-Cys) were 137 nm in length (measured by zetasizer) with a negative surface charge (−28.4 mV). The GNR@Alg-Cys showed an intense absorption at 800 nm, indicating the potential of GNR@Alg-Cys for NIR-excited photothermal therapy (PTT). To target cancer cells, a cyclic peptide, c(RGDfK)KKK, was further modified on GNR@Alg-Cys (denoted as GNR@Alg-Cys/RGD). In vitro experiments reveal the apparently enhanced cell viability under a high dose of GNRs as well as the death of SAS-3 cell lines exposed to a single-wavelength laser (808 nm). The animal study revealed that the volume of GNR@Alg-Cys/RGD-treated laser-exposed tumor was reduced five times when compared with that in the case of the control group (PBS-treated tumor). Furthermore, the in vivo toxicity of GNR@Alg-Cys/RGD was evaluated, and no significant effect was observed on the functions of liver and kidneys after PTT.
Encapsulating cisplatin (CDDP) into liposomes to form lipid-platinum-chloride nanoparticles (LPC NPs) has shown a promising anticancer effect in melanoma, bladder, and liver cancer models. This promising anticancer effect of LPC NPs challenges us to study its implications in combination with photodynamic therapy (PDT). Herein, we report the therapeutic efficacy of PDT+LPC on a xenograft model of oral squamous cell carcinoma (OSCC). Results showed that PDT+LPC significantly reduced the tumor volume by up to ~112%. Meanwhile, LPC, PDT+CDDP, or the CDDP group showed ~98.8%, ~73.1%, or ~39.5% volume reductions, respectively. Histological examination suggests that PDT+LPC or LPC treatment showed minimal side effects on renal damage compared to either CDDP or the PDT+CDDP group. Immunohistochemistry staining (IHC) staining on Ki-67, CD31, cleaved caspase-3, TUNEL assays, and western blots of tumor suppressor p53 confirmed consistent results. Most importantly, PDT+LPC prolonged tumor growth inhibition, which leads to minimum chemotherapy treatment administrations. Results suggest that PDT cytotoxicity provided a potent additive effect towards chemotherapy efficacy. Therefore, combined PDT with LPC NPs enhanced the therapeutic outcome in human OSCC.
1 September 2014 in Photodiagnosis and Photodynamic Therapy